Targeting Plasmodium Metabolism to Improve Antimalarial Drug Design.
2016
Malaria is one of the main infectious diseases in tropical developing countries and represents high morbidity
and mortality rates nowadays. The principal etiological agent P. falciparum is transmitted through the bite of the female
Anopheles mosquito. The issue has escalated due to the emergence of resistant strains to most of the antimalarials used for
the treatment including Chloroquine, Sulfadoxine-Pyrimethamine, and recently Artemisinin derivatives, which has led to
diminished effectiveness and by consequence increased the severity of epidemic outbreaks. Due to the lack of effective
compounds to treat these drug-resistant strains, the discovery or development of novel anti-malaria drugs is important. In
this context, one strategy has been to find inhibitors of enzymes, which play an important role for parasite survival. Today,
promising results have been obtained in this regard, involving the entire P. falciparum metabolism. These inhibitors
could serve as leads in the search of a new chemotherapy against malaria. This review focuses on the achievements in recent
years with regard to inhibition of enzymes used as targets for drug design against malaria.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI